Heart failure with preserved ejection fraction
Drug research and approvals for heart failure with preserved ejection fraction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 139 studies of heart failure with preserved ejection fraction are recruiting on ClinicalTrials.gov, and Health Canada has authorized 18 drug trials for it since 2013.
- Recruiting worldwide: 139
- Trials authorized in Canada: 18
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 139 recruiting on ClinicalTrials.gov ↗- AlEX-DHF: Ablation and Exercise in Diastolic Heart FailureNCT06650995 · Not applicable · Technical University of Munich · starts Feb 1, 2027
- Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection FractionNCT06217120 · Phase 2 · Montreal Heart Institute · starts Nov 6, 2026
- The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)NCT07855692 · Phase 2 · Nagoya University · starts Nov 5, 2026
- PrEcision Pacing in HFpEF: the PEP-HFpEF TrialNCT07864558 · Not applicable · Tufts Medical Center · starts Nov 1, 2026
- Exercise Cardiovascular Magnetic Resonance In Heart Failure With Preserved Ejection FractionNCT07401771 · Not reported · Mayo Clinic · starts Nov 1, 2026
- HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to…NCT07123779 · Phase 1 / Phase 2 · 35Pharma Inc., a GSK company · starts Oct 21, 2026
- Effects of a Specialized Diabetes and Heart Clinic and Detection of Unrecognized Heart Failure in People With Type 2…NCT07878325 · Not applicable · Odense University Hospital · starts Oct 20, 2026
- Resmetirom in Patients With MASH and HFpEFNCT07830758 · Phase 1 · Madrigal Pharmaceuticals, Inc. · starts Oct 16, 2026
- Bundle Branch Pacing to Preserve Ejection Fraction in Atrial Fibrillation TrialNCT07759700 · Not applicable · Poitiers University Hospital · starts Oct 15, 2026
- Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart FailureNCT07575672 · Phase 3 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Oct 9, 2026
Trials Authorized in Canada
The 10 newest of 18; search them all in Canada trials| Jun 25, 2025 | A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of maridebart cafraglutide on mortality and morbidity in…MARIDEBART CAFRAGLUTIDE (AMG 133) | Amgen | Ongoing |
| Jan 30, 2025 | Phase 2, multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of cdr132l on reverse cardiac remodelling in participants with…CDR132L | Novo Nordisk | Ongoing |
| Feb 27, 2024 | A phase 3, double-blind, randomized, placebo-controlled study of levosimendan in pulmonary hypertension patients with heart failure and preserved left…LEVOSIMENDAN (TNX-103) | TENAX THERAPEUTICS INC | Ongoing |
| Dec 11, 2023 | Athena: effects of ziltivekimab versus placebo on heart failure symptoms and physical fonction i patients with heart failure with mildly reduced or preserved…ZILTIVEKIMAB | Novo Nordisk | Ongoing |
| Nov 8, 2023 | A phase 2a, double-blind, randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of…DELOCAMTEN (BMS-986435, MYK-224) | Bristol-Myers Squibb | Ongoing |
| Dec 20, 2022 | Hermes: effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and…ZILTIVEKIMAB | Novo Nordisk | Ongoing |
| Sep 9, 2022 | A phase 2, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of ly3540378 in adults with worsening chronic heart…LY3540378 (VOLENRELAXIN) | Eli Lilly | Ongoing |
| Dec 21, 2021 | A biomarker study assessing the effects of colchicine on inflammation and extra-cellular matrix turnover in patients with heart failure and preserved ejection…COLCHICINE | MONTREAL HEART INSTITUTE | Closed |
| Mar 18, 2020 | A phase 2, multicentre, double-blind, placebo and active control efficacy and safety study to evaluate verinurad combined with allopurinol in heart failure…VERINURAD/ ALLOPURINOL | AstraZeneca Pharmaceuticals LP | Closed |
| May 2, 2019 | A multi-center, double-blind, placebo-controlled phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved…MACITENTAN | Johnson & Johnson | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA